Wells Fargo & Company Issues Positive Forecast for Insulet (NASDAQ:PODD) Stock Price

Insulet (NASDAQ:PODD) had its price target upped by Wells Fargo & Company from $144.00 to $172.00 in a research note published on Thursday,Benzinga reports. They currently have an equal weight rating on the medical instruments supplier’s stock.

PODD has been the subject of a number of other research reports. Citigroup lifted their target price on shares of Insulet from $165.00 to $172.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 8th. Royal Bank Of Canada cut their price target on shares of Insulet from $245.00 to $160.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. UBS Group decreased their price target on Insulet from $174.00 to $150.00 and set a “neutral” rating for the company in a report on Thursday, August 6th. Jefferies Financial Group reiterated a “buy” rating and set a $200.00 price target on shares of Insulet in a report on Wednesday. Finally, Robert W. Baird set a $175.00 price objective on Insulet in a research report on Thursday, August 6th. Thirteen research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $192.36.

Insulet Stock Performance

NASDAQ:PODD opened at $156.12 on Thursday. The company has a market capitalization of $10.83 billion, a PE ratio of 25.43, a P/E/G ratio of 1.25 and a beta of 1.06. The company has a 50 day simple moving average of $141.91 and a two-hundred day simple moving average of $177.34. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.83 and a current ratio of 2.51. Insulet has a fifty-two week low of $126.40 and a fifty-two week high of $354.88.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.59 by $0.40. Insulet had a net margin of 13.44% and a return on equity of 31.76%. The firm had revenue of $842.00 million during the quarter, compared to analyst estimates of $832.63 million. During the same quarter last year, the business earned $1.24 EPS. The company’s revenue was up 19.2% compared to the same quarter last year. Research analysts anticipate that Insulet will post 6.76 earnings per share for the current year.

Institutional Trading of Insulet

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PODD. BlackRock Inc. purchased a new position in Insulet during the 2nd quarter worth $1,018,582,000. Arrowstreet Capital Limited Partnership grew its stake in shares of Insulet by 462.7% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock worth $258,088,000 after acquiring an additional 1,011,369 shares in the last quarter. Man Group plc purchased a new stake in shares of Insulet in the second quarter valued at about $78,746,000. Amundi raised its holdings in shares of Insulet by 13.6% in the second quarter. Amundi now owns 507,847 shares of the medical instruments supplier’s stock valued at $77,320,000 after purchasing an additional 60,929 shares during the last quarter. Finally, Bank of America Corp DE purchased a new stake in shares of Insulet in the second quarter valued at about $64,921,000.

Key Headlines Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet reported Q3 adjusted EPS of $1.99, above the $1.59 consensus, while revenue rose 19.2% year over year to $842 million and also topped estimates. The company announced a $1 billion share-repurchase program and updated its 2026 outlook. Insulet Q3 earnings and revenue beat
• Positive Sentiment: Several analysts lifted their price targets after the results. Bernstein raised its target to $200 and kept an outperform rating; RBC raised its target to $180 and also maintained outperform, while Canaccord reiterated Buy at $179. RBC price-target update
• Neutral Sentiment: Other target increases came with cautious ratings: JPMorgan and Citi moved to $170, UBS to $171, and Wells Fargo to $172, while retaining neutral or equal-weight stances. RBC sees valuation as attractive but notes a more conservative 2027 outlook. RBC valuation and outlook commentary
• Negative Sentiment: Management cautioned that growth may slow in 2027 and that competitors could take some share from Omnipod. Those forward-looking concerns may be outweighing the strong quarter and contributing to the stock’s decline. CEO comments on growth and competition

Insulet Company Profile

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.